CRISPR Therapeutics AG (CRSP)
NGM – Real vaqt narxi. Valyuta: USD
52.83
-1.18 (-2.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NGM – Real vaqt narxi. Valyuta: USD
52.83
-1.18 (-2.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
CRISPR Therapeutics AG, gen tahrirlash kompaniyasi, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platformasidan foydalanib, insonning jiddiy kasalliklari uchun gen asosidagi dori vositalarini ishlab chiqishga qaratilgan. Kompaniyaning CRISPR/Cas9 texnologiyasi gen tahrirlash uchun mo'ljallangan bo'lib, bu genomik DNKning ma'lum bir ketma-ketligini aniq o'zgartirish jarayonidir. Kompaniya gemoglobinopatiyalar, CAR T hujayrali terapiyalar, in vivo va 1-toifali diabet kabi turli kasallik sohalarida terapevtik dasturlar portfeliga ega, shuningdek, avtoimmun ko'rsatmalar va onkologiya uchun allogenik kimera antigen retseptorlari T hujayrasiga qaratilgan avtologik, gen tahrirlangan CAR T dasturi, shu jumladan, tadqiqotdagi CAR T dasturlarini ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodi CASGEVY bo'lib, bu transfüzyon-bog'liq beta-talassemiya, og'ir o'roqsimon hujayrali kasallik (SCD) va gemoglobinopatiyalardan aziyat chekayotgan bemorlarni davolash uchun mo'ljallangan ekz-CRISPR/Cas9 gen tahrirlangan hujayra terapiyasidir, bunda bemorning gemopoetik ildiz va progenitor hujayralari qizil qon hujayralarida yuqori darajadagi homila gemoglobinini ishlab chiqarish uchun tahrirlanadi. Shuningdek, kompaniya onkologiya va avtoimmun ko'rsatmalar uchun CD19 ga yo'naltirilgan CTX112 va CD70 ga yo'naltirilgan CTX131, shu jumladan CAR T hujayrali terapiyalarini ishlab chiqadi; CTX310 va CTX320, angiopoietin-like protein 3 va lipoproteinning tasdiqlangan maqsadlarini buzish orqali yurak-qon tomir kasalliklarini davolash uchun in vivo gen tahrirlash; va T1D ni davolash uchun allogenik, gen tahrirlangan, gipoimmun ildiz hujayralaridan olingan mahsulot nomzodi CTX211. Kompaniya Vertex Pharmaceuticals Incorporated bilan strategik hamkorlikka ega. CRISPR Therapeutics AG 2013 yilda tashkil etilgan va markazi Shveytsariyaning Zug shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Chad A. Cowan Ph.D. | Scientific Founder |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Naimish Patel C.M., M.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-04 | 8-K | crsp-20260504.htm |
| 2026-05-04 | 10-Q | crsp-20260331.htm |
| 2026-04-21 | ARS | 2025_ars_for_2026_proxy.pdf |
| 2026-04-02 | PRE 14A | crsp-20260402.htm |
| 2026-03-16 | 8-K | crsp-20260316.htm |
| 2026-03-11 | 8-K | crsp-20260310.htm |
| 2026-02-12 | 10-K | crsp-20251231.htm |
| 2026-01-12 | 8-K | crsp-20260112.htm |
| 2025-11-10 | 8-K | crsp-20251110.htm |
| 2025-10-15 | 8-K | crsp-20251015.htm |
| Chief Medical Officer |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer |
| Dr. Samarth Kulkarni Ph.D. | CEO & Chairman |
| Mr. James R. Kasinger J.D. | General Counsel & Secretary |
| Mr. Shaun Foy CFA | Co-Founder |